Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 15Phase 1/2 4Phase NA 2Phase 3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 49Terminated 12Withdrawn 8Unknown 4Recruiting 4Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 155Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 92Pancreatic Neoplasms 80Neoplasm Metastasis 80Leukemia, Myeloid, Acute 79Recurrence 76Melanoma 74Prostatic Neoplasms 73Ovarian Neoplasms 73Multiple Myeloma 66Stomach Neoplasms 59Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

nilotinib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1fludarabine phosphate 1asciminib 1Mycophenolic Acid 1Mesna 1Melphalan 1Filgrastim 1Dasatinib 1Cyclophosphamide 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT04925479 2026-04-30

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Novartis

Phase 1/2 Recruiting
34 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

Phase 1/2 Recruiting
12 enrolled
Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06163430 2026-01-12

CARDINAL

Terns, Inc.

Phase 1/2 Recruiting
180 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04835584 2022-03-21

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Kartos Therapeutics, Inc.

Phase 1/2 Recruiting
109 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡